CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis®
- CureVac recognized as a Top 100 innovator in acknowledgment of the company’s innovative strength and extensive intellectual property portfolio
- The company holds one of broadest intellectual property portfolios in mRNA technology
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced its inclusion in the second annual “Innovation Momentum: The Global Top 100” report by LexisNexis®. The Top 100 recognizes companies advancing innovative solutions to address today’s challenges and laying the intellectual property foundations for further breakthroughs. The LexisNexis® report identifies companies shaping the future of science and technology by analyzing shifts in patent portfolio strength over the last two years.